Developer docs
API playgroundTry for free, no card

Search company profiles

Effimune

Full company profile

uuid000s6yf

Namestring
Effimune
Legal namestring
OSE Immunotherapeutics
Websiteurl
effimune.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Effimune, operating through OSE Immunotherapeutics, is a clinical-stage biotechnology company founded in 2007 and headquartered in Nantes, France, with additional offices in Paris. The company researches and develops drugs for transplantation and immune-mediated diseases, focusing on first-in-class immunotherapies in Immuno-Oncology and Immuno-Inflammation. Its pipeline comprises seven candidates spanning therapeutic cancer vaccines (Tedopi, OSE-279), immune-regulation antibodies (Lusvertikimab/OSE-127, Pegrizeprument/FR104), partnered assets (BI 770371 with Boehringer Ingelheim; ABBV-230 with AbbVie), and a preclinical myeloid checkpoint program (CLEC-1).

The underlying science rests on three patented research platforms: (1) a neoepitope-based platform that activates cytotoxic T cells for cancer indications, (2) a tumor-microenvironment platform that converts suppressive cells into effector cells, and (3) an immune-regulation platform that downregulates effector T cells and upregulates regulatory T cells for autoimmune and inflammatory conditions. The lead program, Tedopi, is in a Phase 3 pivotal trial (ARTEMIA) in non-small cell lung cancer, and has received two positive Independent Data Monitoring Committee reviews as of February 2026.

The business model is pre-commercial: the company generates no product revenue today, relying instead on capital markets (it is listed on Euronext Paris under ticker OSE) and pharmaceutical partnerships for development funding. Future commercialization would occur through partner-led distribution channels following regulatory approval, targeting oncology and immunology patients via healthcare providers. The organization is small (11-50 employees) and R&D-intensive, with leadership including a Chief Development and Regulatory Officer overseeing clinical and regulatory execution.

Short descriptiontext

Effimune, operating as OSE Immunotherapeutics, is a Nantes-based clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases through three patented research platforms and a seven-asset pipeline led by a Phase 3 therapeutic cancer vaccine for non-small cell lung cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNantes, France
HQ citystring
Nantes
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy drugs, therapeutic cancer vaccines, immune modulation therapies, clinical stage biotech, immuno-oncology treatments
Industry4 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Immunotherapy Drugs
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Tedopi®
Description

Therapeutic cancer vaccine in Phase 3 clinical trial (ARTEMIA) for non-small cell lung cancer

ose-immuno.com
+6 more records
Core offering1 text field

Effimune is a biotechnology company that conducts research and development of drugs for transplantation and immune-mediated diseases. Its pipeline spans immuno-oncology (including therapeutic cancer vaccines for non-small cell lung cancer) and immuno-inflammation (antibody-based therapies), supported by three proprietary patented research platforms. The company operates as a clinical-stage developer, advancing first-in-class immunotherapy candidates both independently and through pharmaceutical partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Second positive IDMC review for Phase 3 ARTEMIA trial of Tedopi in NSCLC
Product overview1 text field

OSE Immunotherapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class immunotherapies for Immuno-Oncology and Immuno-Inflammation. The company's product portfolio includes seven distinct therapeutic candidates: Tedopi® (a therapeutic cancer vaccine in Phase 3 for non-small cell lung cancer), OSE-279, Lusvertikimab (OSE-127), Pegrizeprument (FR104), BI 770371, ABBV-230, and CLEC-1. These products are developed through three proprietary preclinical research platforms focused on delivering next-generation immunotherapy treatments through activation of cytotoxic T cells, transformation of suppressive tumor microenvironment cells, and regulation of immune responses.

Product and service1 record
1Tedopi®
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Effimune

Cancer Immunotherapy Drugseffimune.com

Effimune, operating as OSE Immunotherapeutics, is a Nantes-based clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases through three patented research platforms and a seven-asset pipeline led by a Phase 3 therapeutic cancer vaccine for non-small cell lung cancer.

What Effimune does

Effimune, operating through OSE Immunotherapeutics, is a clinical-stage biotechnology company founded in 2007 and headquartered in Nantes, France, with additional offices in Paris. The company researches and develops drugs for transplantation and immune-mediated diseases, focusing on first-in-class immunotherapies in Immuno-Oncology and Immuno-Inflammation. Its pipeline comprises seven candidates spanning therapeutic cancer vaccines (Tedopi, OSE-279), immune-regulation antibodies (Lusvertikimab/OSE-127, Pegrizeprument/FR104), partnered assets (BI 770371 with Boehringer Ingelheim; ABBV-230 with AbbVie), and a preclinical myeloid checkpoint program (CLEC-1).

The underlying science rests on three patented research platforms: (1) a neoepitope-based platform that activates cytotoxic T cells for cancer indications, (2) a tumor-microenvironment platform that converts suppressive cells into effector cells, and (3) an immune-regulation platform that downregulates effector T cells and upregulates regulatory T cells for autoimmune and inflammatory conditions. The lead program, Tedopi, is in a Phase 3 pivotal trial (ARTEMIA) in non-small cell lung cancer, and has received two positive Independent Data Monitoring Committee reviews as of February 2026.

The business model is pre-commercial: the company generates no product revenue today, relying instead on capital markets (it is listed on Euronext Paris under ticker OSE) and pharmaceutical partnerships for development funding. Future commercialization would occur through partner-led distribution channels following regulatory approval, targeting oncology and immunology patients via healthcare providers. The organization is small (11-50 employees) and R&D-intensive, with leadership including a Chief Development and Regulatory Officer overseeing clinical and regulatory execution.

Effimune firmographics

Firmographics
Name
Effimune
Legal name
OSE Immunotherapeutics
Website
https://effimune.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Effimune, operating as OSE Immunotherapeutics, is a Nantes-based clinical-stage biotechnology company developing first-in-class immunotherapies for cancer and immune-mediated diseases through three patented research platforms and a seven-asset pipeline led by a Phase 3 therapeutic cancer vaccine for non-small cell lung cancer.
Ownership category
akta.pro rank

Effimune industry classification

Industry
Product category
Cancer Immunotherapy Drugs
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
SECONDARYHLAAAEAK
Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Cancer immunotherapy drugs
  • Therapeutic cancer vaccines
  • Immune modulation therapies
  • Clinical stage biotech
  • Immuno-oncology treatments

Where Effimune is headquartered

Location

Headquarters

HQ city
Nantes
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Effimune business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Marketing channels4 records

Effimune product offering

Product offering

Core offering

Effimune is a biotechnology company that conducts research and development of drugs for transplantation and immune-mediated diseases. Its pipeline spans immuno-oncology (including therapeutic cancer vaccines for non-small cell lung cancer) and immuno-inflammation (antibody-based therapies), supported by three proprietary patented research platforms. The company operates as a clinical-stage developer, advancing first-in-class immunotherapy candidates both independently and through pharmaceutical partnerships.

Product overview

OSE Immunotherapeutics is a clinical-stage biotechnology company developing a portfolio of first-in-class immunotherapies for Immuno-Oncology and Immuno-Inflammation. The company's product portfolio includes seven distinct therapeutic candidates: Tedopi® (a therapeutic cancer vaccine in Phase 3 for non-small cell lung cancer), OSE-279, Lusvertikimab (OSE-127), Pegrizeprument (FR104), BI 770371, ABBV-230, and CLEC-1. These products are developed through three proprietary preclinical research platforms focused on delivering next-generation immunotherapy treatments through activation of cytotoxic T cells, transformation of suppressive tumor microenvironment cells, and regulation of immune responses.

Differentiator

Problem solved

Functional benefit

Brands

  • Tedopi®: Therapeutic cancer vaccine in Phase 3 clinical trial (ARTEMIA) for non-small cell lung cancer
  • OSE-279
  • Lusvertikimab (OSE-127)
  • Pegrizeprument (FR104)
  • BI 770371
  • ABBV-230
  • CLEC-1

Products and services

  • Tedopi®

Quantifiable outcome

  • Second positive IDMC review for Phase 3 ARTEMIA trial of Tedopi in NSCLC

Companies that use Effimune

Customer profile

Segments1 record

Ideal customer profiles2 records

Effimune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Effimune partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights4 records

Effimune competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

Effimune social profiles

Digital presence

Effimune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Effimune leadership team

Management profile

Number of profiles

Profiles1 record

Effimune funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Effimune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Effimune

What does Effimune do?

Effimune is a biotechnology company that conducts research and development of drugs for transplantation and immune-mediated diseases. Its pipeline spans immuno-oncology (including therapeutic cancer vaccines for non-small cell lung cancer) and immuno-inflammation (antibody-based therapies), supported by three proprietary patented research platforms. The company operates as a clinical-stage developer, advancing first-in-class immunotherapy candidates both independently and through pharmaceutical partnerships.

Is Effimune a public or private company?

Effimune is a public company. It is classified as unknown and is currently operating.

When was Effimune founded?

Effimune was founded in 2007. It employs 1 to 10 people.

Where is Effimune based?

Effimune is headquartered in Nantes, France, in the Europe region.

Does Effimune have an API?

No public API is recorded for Effimune.

What industry is Effimune in?

Effimune's product category is Cancer Immunotherapy Drugs. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales